

Simplexa™ HSV 1 & 2 Direct Kit

A Comprehensive HSV 1 & 2 Molecular Test for CSF, Cutaneous and Mucocutaneous Swab Samples

Direct detection and differentiation of HSV 1 & HSV 2

The quality of treatment starts with diagnosis.

Comprehensive, Fast and Accurate Molecular HSV Testing

Direct detection and differentiation of HSV 1 & HSV 2 in CSF **and** cutaneous/mucocutaneous lesion swabs

HSV causes a wide spectrum of clinical manifestations

Herpes Simplex Virus (HSV 1 & 2) can cause a variety of diseases with multiple presentations, ranging from mucocutaneous oral and genital lesions to fulminate encephalitis.

HSV is a common cause of meningitis and encephalitis. Encephalitis occurs in all ages, from neonates to adults, and during all seasons. HSV encephalitis may have devastating results. Untreated HSV central nervous system (CNS) infection can reach mortality rates as high as 70% and for those who survive, only a minority will achieve full recovery.

HSV is also one of the most common causes of sexually transmitted disease. An estimated 3.7 billion have HSV 1 infection globally and an estimated 417 million have HSV 2 infection.¹ Recognition of genital herpes is important to prevent transmission and provide counseling.

First of its kind coverage for HSV testing needs

- **Comprehensive sample types:**
For use with CSF and cutaneous/mucocutaneous lesion swabs.
- **The smallest sample volume:**
Only requires 50 µL of precious CSF sample.
- **Fast and easy workflow:**
CLIA moderate complexity with results in about an hour.
- **Direct sample-to-answer workflow:**
No DNA extraction needed.



Streamlined, simple workflow



The Simplexa™ HSV 1 & 2 Direct assay is a CLIA moderate complexity assay. The LIAISON MDX® provides results in about an hour bypassing conventional DNA extraction procedures.

Accurate performance for confidence when testing multiple different sample types

Consolidate your CSF, cutaneous and mucocutaneous lesion swab testing.

CSF Clinical Agreement²

Population	HSV 1		HSV 2	
	Agreement with Positives	Agreement with Negatives	Agreement with Positives	Agreement with Negatives
Encephalitis Patients	100.0% (3/3) 95% CI: 43.8% to 100.0%	98.8% (159/161) 95% CI: 95.6% to 99.7%	85.7% (6/7) 95% CI: 48.7% to 99.9%	99.4% (156/157) 95% CI: 96.5% to 99.9%
HSV Molecular Positive Patients	100.0% (13/13) 95% CI: 77.2% to 100.0%	N/A	100.0% (42/42) 95% CI: 91.6% to 100.0%	N/A

Cutaneous & Mucocutaneous Clinical Agreement²

Retrospective Population	HSV 1		HSV 2	
	Agreement with Positives	Agreement with Negatives	Agreement with Positives	Agreement with Negatives
Cutaneous Lesion Swabs	100.0% (63/63) 95% CI: 94.3% to 100.0%	100.0% (119/119) 95% CI: 96.9% to 100.0%	100.0% (60/60) 95% CI: 94.0% to 100.0%	100.0% (122/122) 95% CI: 96.9% to 100.0%
Mucocutaneous Lesion Swabs	100.0% (58/58) 95% CI: 93.8% to 100.0%	100.0% (119/119) 95% CI: 96.9% to 100.0%	100.0% (59/59) 95% CI: 93.9% to 100.0%	100.0% (118/118) 95% CI: 96.8% to 100.0%

Everything you need for molecular HSV testing



Ordering information – Simplexa™ HSV 1 & 2 Direct

CATALOG NUMBER	DESCRIPTION	REACTIONS/KIT
MOL2150	Simplexa™ HSV 1 & 2 Direct Kit*	24
MOL2160	Simplexa™ HSV 1 & 2 Positive Control Pack	10 x 100 µL

*To be used with Direct Amplification discs (3 DAD discs, MOL1455).

Products for VZV testing



Ordering information – Simplexa™ VZV Direct

CATALOG NUMBER	DESCRIPTION	REACTIONS/KIT
MOL3650	Simplexa™ VZV Direct Kit*	24
MOL3660	Simplexa™ VZV Positive Control Pack	10

*To be used with Direct Amplification discs (3 DAD discs, MOL1455).



The Diagnostic Specialist



p: +39 0161 487526

p: +1 (562) 240-6500

e: cs.molecular@diasorin.com

w: www.molecular.diasorin.com

Simplexa, LIAISON MDX, and the associated logos are all trademarks or registered trademarks of DiaSorin Molecular LLC, or its affiliate, in the U.S. and/or other countries. ©2016 DiaSorin Molecular LLC. All rights reserved.

Black Hole Quencher, CAL Fluor, Quasar dyes are trademarks of Biosearch Technologies, Inc. DiaSorin products incorporating the Black Hole Quencher, CAL Fluor, and Quasar dye technology are licensed and sold pursuant to an agreement with Biosearch Technologies, Inc., and these products are sold exclusively for clinical, diagnostic, or research and development purposes.

Product availability subject to required regulatory approvals.

FOR OUTSIDE THE US AND/OR CANADA ONLY

M0870004340
VER: OUSHSVBR1017c